B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
FASEB BioAdvances · 2023-04 · 5 (4) · 156-170
DOI: 10.1096/fba.2023-00009 ↗Kurz gefasst
Fachartikel in der Zeitschrift FASEB BioAdvances, online erschienen am 16.02.2023. Verfasst von Susan Raju Paul und 31 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Immunotherapy Center, Massachusetts General Hospital Charlestown Massachusetts USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Lung cancer is the leading cause of cancer‐related deaths worldwide. Surgery and chemoradiation are the standard of care in early stages of non‐small cell lung cancer (NSCLC), while immunotherapy is the standard of care in late‐stage NSCLC. The immune composition of the tumor microenvironment (TME) is recognized as an indicator for responsiveness to immunotherapy, although much remains unknown about its role in responsiveness to surgery or chemoradiation. In this pilot study, we characterized the NSCLC TME using mass cytometry (CyTOF) and bulk RNA sequencing (RNA‐Seq) with deconvolution of RNA‐Seq being performed by Kassandra, a recently published deconvolution tool. Stratification of patients based on the intratumoral abundance of B cells identified that the B‐cell rich patient group had increased expression of CXCL13 and greater abundance of PD1 + CD8 T cells. The presence of B cells and PD1 + CD8 T cells correlated positively with the presence of intratumoral tertiary lymphoid structures (TLS). We then assessed the predictive and prognostic utility of these cell types and TLS within publicly available stage 3 and 4 lung adenocarcinoma (LUAD) RNA‐Seq datasets. As previously described by others, pre‐treatment expression of intratumoral 12‐chemokine TLS gene signature is associated with progression free survival (PFS) in patients who receive treatment with immune checkpoint inhibitors (ICI). Notably and unexpectedly pre‐treatment percentages of intratumoral B cells are associated with PFS in patients who receive surgery, chemotherapy, or radiation. Further studies to confirm these findings would allow for more effective patient selection for both ICI and non‐ICI treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine and Immunotherapy Center, Massachusetts General Hospital Charlestown Massachusetts USA.
- Department of Medicine Massachusetts General Hospital Boston Massachusetts USA.
- Harvard Medical School Boston Massachusetts USA.
- BostonGene Waltham Massachusetts USA.
- Department of Thoracic Surgery Massachusetts General Hospital Boston Massachusetts USA.
- Cancer Center, Massachusetts General Hospital Boston Massachusetts USA.
Zitieren
APA
Raju Paul, S., Valiev, I., Korek, S. E., Zyrin, V., Shamsutdinova, D., Gancharova, O., Zaitsev, A., Nuzhdina, E., Davies, D. L., Dagogo-Jack, I., Frenkel, F., Brown, J. H., Hess, J. M., Viet, S., Petersen, J. L., Wright, C. D., Ott, H. C., Auchincloss, H. G., Muniappan, A., …, & Poznansky, M. C. (2023). B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas. FASEB BioAdvances, 5(4), 156-170. https://doi.org/10.1096/fba.2023-00009
Vancouver
Raju Paul S, Valiev I, Korek SE, Zyrin V, Shamsutdinova D, Gancharova O, et al. B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas. FASEB BioAdvances. 2023;5(4):156-170. doi:10.1096/fba.2023-00009
BibTeX
@article{RajuPaul2023,
author = {Raju Paul, Susan and Valiev, Ivan and Korek, Skylar E and Zyrin, Vladimir and Shamsutdinova, Diana and Gancharova, Olga and Zaitsev, Alexander and Nuzhdina, Ekaterina and Davies, Diane L and Dagogo-Jack, Ibiayi and Frenkel, Felix and Brown, Jessica H and Hess, Joshua M and Viet, Sarah and Petersen, Jason L and Wright, Cameron D and Ott, Harald C and Auchincloss, Hugh G and Muniappan, Ashok and Shioda, Toshihiro and Lanuti, Michael and Davis, Christel M and Ehli, Erik A and Hung, Yin P and Mino-Kenudson, Mari and Tsiper, Maria and Sluder, Ann E and Reeves, Patrick M and Kotlov, Nikita and Bagaev, Alexander and Ataullakhanov, Ravshan and Poznansky, Mark C},
title = {B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas},
journal = {FASEB BioAdvances},
year = {2023},
volume = {5},
number = {4},
pages = {156--170},
doi = {10.1096/fba.2023-00009}
}
EUVIMED